Looking Into Meridian Bioscience’s Return On Capital Employed
Meridian Bioscience (NASDAQ:VIVO) brought in sales totaling $67.77 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 125.52%, resulting in a loss of $7.34 million.
Meridian Bioscience: Q3 Earnings Insights
Meridian Bioscience (NASDAQ:VIVO) reported its Q3 earnings results on Friday, August 5, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Meridian Bioscience Q3 EPS $0.16, Inline, Sales $67.80M Beat $66.82M Estimate
Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 27.27 percent decrease over earnings of $0.22 per share from the same period last year.
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell
• Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
Preview: Meridian Bioscience’s Earnings
Meridian Bioscience (NASDAQ:VIVO) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement.
Analysts estimate that Meridian Bioscience will report an earnings per share (EPS) of $0.16.
Recap Of Friday’s Biotech Catalysts – End of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE…
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34
HC Wainwright & Co. analyst Yi Chen downgrades Meridian Bioscience (NASDAQ:VIVO) from Buy to Neutral and raises the price target from $30 to $34.
Meridian Bioscience To Be Acquired By SD Biosensor, SJL Partners – Read For How Much
SD Biosensor Inc (SDB) and SJL Partners LLC have agreed to acquire Meridian Bioscience Inc (NASDAQ:VIVO) in an all-cash transaction valued…